Pharm Exec

FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy

FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...
PharmExec

FDA Approves Hepcludex as First and Only Approved Treatment for Chronic Hepatitis Delta Virus

FDA approves Gilead’s Hepcludex as the first treatment for chronic hepatitis delta virus in the U.S., marking a major ...
PharmExec

Pharmaceutical Executive Daily: FDA Approves Hepcludex

In today’s Pharmaceutical Executive Daily, Eli Lilly announces three acquisitions totaling roughly $3 billion, the FDA ...
PharmExec

FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates

Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall ...
Pharm Exec

CVS Restores Coverage of Lilly’s Zepbound, Adds Oral Obesity Drug Foundayo

Zepbound’s return as a preferred option reverses a prior formulary exclusion that maintained Wegovy coverage, underscoring how net pricing and rebate contracting drive PBM obesity access decisions.
PharmExec

Pharma Roundup: Mounjaro Shows Advantages in Type 2 Diabetes, Immune System Linked to Long Covid Symptoms

Surpass-Early randomized ~800 adults with ≤4-year type 2 diabetes on metformin to add tirzepatide or intensify care, predominantly with semaglutide or dulaglutide comparators. At two years, ...
PharmExec

Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion

Eli Lilly enters three separate acquisitions totaling $3.83 billion in a push into vaccines and infectious diseases, signaling a strategic expansion into prevention-focused medicines. Eli Lilly ...
PharmExec

WHO Prioritizes Three Experimental Treatments for Bundibugyo Ebola Strain

WHO identifies experimental therapies from Mapp Biopharmaceutical, Regeneron, and Gilead as leading candidates for the Bundibugyo strain of Ebola virus disease, as the agency pushes for urgent ...
Pharm Exec

FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant

VRBPAC is evaluating an XFG-targeted composition for 2026–2027 vaccines, based on CDC variant prevalence estimates that are more than a month old. FDA briefing materials emphasize eroding sequencing ...
PharmExec

Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration

The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...
PharmExec

Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo

In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s ...
Pharm Exec

Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio

Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...